Survodutide for Liver: What the Evidence Shows
What human and animal studies show about Survodutide for liver, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 3
- with an outcome for liver, in our evidence file (PubMed search, 2 Oct 2026)
- Animal studies
- None found
- with an outcome for liver, in our evidence file (PubMed search, 2 Oct 2026)
- Studies we summarised
- 3
- with an outcome for liver
Evidence for liver
Each row is an outcome related to liver from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Liver fat reduction of 30% or more | 84.2% on survodutide versus 24.3% on placebo had a 30% or greater liver fat reduction (efficacy estimand); 68.5% versus 28.6% (treatment regimen estimand). | Human RCTn = 216 | Nature medicine 2026, PMID 42252333 |
| Body weight | Body weight changed by -12.2% with survodutide versus -1.0% with placebo (efficacy estimand). | Human RCTn = 216 | Nature medicine 2026, PMID 42252333 |
| MASH improvement without worsening of fibrosis (primary) | MASH improved without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg) and 43% (6.0 mg) versus 14% with placebo. | Human RCTn = 293 | The New England journal of medicine 2024, PMID 38847460 |
| Liver fat reduction of 30% or more | A 30% or greater liver fat decrease occurred in 63%, 67% and 57% across doses versus 14% with placebo. | Human RCTn = 293 | The New England journal of medicine 2024, PMID 38847460 |
| Liver and metabolic markers in cirrhosis | Liver fat content, liver stiffness, liver volume and body weight were generally reduced after 28 weeks (non-randomised, open-label). | Human uncontrolled trial | Journal of hepatology 2024, PMID 38857788 |
Survodutide and liver are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Liver disease, and the survodutide MASH work
MedlinePlus says imaging tests and liver function tests can check for liver damage and help diagnose liver diseases.[4]
The phase 2 MASH trial gave once-weekly survodutide at 2.4, 4.8 or 6.0 mg or placebo for 48 weeks to adults with biopsy-confirmed MASH and fibrosis stage F1 to F3.[2]
Its registry record has the liver biopsy histology as the primary outcome after 48 weeks.[5]
What the liver results were
MASH improved without worse fibrosis in 47% on 2.4 mg, 62% on 4.8 mg and 43% on 6.0 mg, against 14% on placebo.[2]
Fibrosis improved by at least one stage in 34%, 36% and 34% of the three survodutide groups, against 22% on placebo.[2]
In the phase 3 SYNCHRONIZE-MASLD trial of survodutide 6.0 mg, 84.2% had a liver fat fall of at least 30% against 24.3% on placebo (efficacy estimand).[1]
The first phase 3 obesity trial registered liver fat relative change at week 76 as a secondary outcome.[6]
Cirrhosis and other liver-specific safety points
In people with cirrhosis, a phase 1 trial found survodutide generally tolerable and not needing pharmacokinetic-related dose adjustment.[3]
Drug-related adverse events in that cirrhosis trial's multiple-dose cohorts were 82.4% in healthy individuals and 87.5% in people with cirrhosis over 28 weeks.[3]
In the MASH trial, nausea was reported by 66% against 23%, diarrhea by 49% against 23% and vomiting by 41% against 4% (survodutide versus placebo).[2]
Other peptides people research for liver
All peptides for liver, comparedCommon questions
Does Survodutide help with liver?
The strongest study we summarise for liver is human rct evidence, across 3 studies with an outcome for liver. A trial result is not an approval; see the legal status.
Is Survodutide approved for liver?
No. Survodutide is not FDA approved for any use, including liver.
What is the best peptide for liver?
There is no single answer. Our liver overview compares each candidate by evidence grade and legal status rather than by popularity.
Does survodutide help fatty liver or MASH?
In the phase 2 MASH trial, MASH improved without worsening fibrosis in a higher share of survodutide groups than placebo, and the authors called for phase 3 trials.[2]
Is survodutide safe in cirrhosis?
A phase 1 trial found it generally tolerable in compensated or decompensated cirrhosis, while calling for more study in MASH-related cirrhosis.[3]
More on Survodutide
Sources
- 1Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2026PMID 42252333Accessed 2 Oct 2026
- 2A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026
- 3Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.Journal of hepatology · 2024PMID 38857788Accessed 2 Oct 2026
- 4Official web pageOfficial web page · web page
- 5Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 6A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.